Date de publication: 30 janvier 2020
Promoteur – Intermédiaire Financier
ITM ISOTOPEN TECHNOLOGIEN MUENCHEN AG
Lieu
Description
The project concerns RDI investments of a proprietary portfolio of nuclear medicine solutions for diagnosis and treatment of cancer, addressing a range of indications such as neuroendocrine tumours, bone metastases or prostate cancers. This portfolio includes new radionuclides and radiopharmaceuticals in various stages of clinical development, covering discovery, pre-clinical and clinical (Phase I-III) and technical validation phases.
Objectifs
The project falls within the scope of the Horizon 2020 programme Societal Challenges (Health, Demographic Change and Wellbeing).
Secteur(s)
- Services - Activités spécialisées, scientifiques et techniques
Montant BEI envisagé (montant approximatif)
EUR 40 million
Coût total (montant approximatif)
EUR 92 million
Aspects environnementaux
The project mainly concerns investments in R&D (process development, clinical studies, regulatory development/production capacity, etc.) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an EIA under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Statut
Signé - 20/12/2019
Clause de non-responsabilité
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).